Filing Flows › Comparisons › GRAL vs BDSX
Grail vs Biodesix: GRAL and BDSX compared
Grail is the larger company: $37.5M of revenue in its latest quarter (Q3 2026) against $24.0M for Biodesix (Q3 2026). Biodesix is growing faster (+10% against +4% a year earlier). Biodesix is more profitable, with an operating margin of -25.4% against -385.3%.
Where the money goes: GRAL and BDSX
Grail (GRAL) · Q3 2026
Grail, Q3 2026: revenue $37.5M (+4% year over year), operating margin -385.3%, net loss $104M, operating cash flow −$74.7M. The chart follows the revenue to costs, profit and cash.
Biodesix (BDSX) · Q3 2026
Biodesix, Q3 2026: revenue $24.0M (+10% year over year), operating margin -25.4%, net loss $8.0M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
| Grail (GRAL) | Biodesix (BDSX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $37.5M | $24.0M |
| Revenue growth, Y/Y | +4% | +10% |
| Operating margin | -385.3% | -25.4% |
| Net earnings | −$104M | −$8.0M |
| Net margin | -275.9% | -33.4% |
| Operating cash flow | −$74.7M | −$7.2M |
| Market value | $6.0B | — |
| Analysts’ mean target | $132.56 | — |
Where the revenue comes from
Grail
- Screening revenue: $37.3M (99%)
- Development Services: $266K (1%)
Biodesix
- Diagnostic Tests: $23.1M (96%)
- Development Services: $986K (4%)
Questions
Which is bigger, Grail or Biodesix?
Grail is the larger company: $37.5M of revenue in its latest quarter (Q3 2026) against $24.0M for Biodesix (Q3 2026).
Is Grail or Biodesix growing faster?
Biodesix is growing faster (+10% against +4% a year earlier).
Which is more profitable, Grail or Biodesix?
Biodesix is more profitable, with an operating margin of -25.4% against -385.3%.
More: Grail earnings · how Grail makes money · Biodesix earnings · how Biodesix makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.